Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen

The Tamoxifen Response by CYP2D6 Genotype‐based Treatment‐1 (TARGET‐1) study (n = 180) was conducted from 2012–2017 in Japan to determine the efficacy of tamoxifen dosing guided by cytochrome P450 2D6 (CYP2D6) genotypes. To predict its outcomes prior to completion, we constructed the comprehensive physiologically based pharmacokinetic (PBPK) models of tamoxifen and its metabolites and performed virtual TARGET‐1 studies. Our analyses indicated that the expected probability to achieve the end point (demonstrating the superior efficacy of the escalated tamoxifen dose over the standard dose in patients carrying CYP2D6 variants) was 0.469 on average. As the population size of this virtual clinical study (VCS) increased, the expected probability was substantially increased (0.674 for n = 260). Our analyses also informed that the probability to achieve the end point in the TARGET‐1 study was negatively impacted by a large variability in endoxifen levels. Our current efforts demonstrate the promising utility of the PBPK modeling and VCS approaches in prospectively designing effective clinical trials.

[1]  Akihiko Konagaya,et al.  Cluster Newton Method for Sampling Multiple Solutions of Underdetermined Inverse Problems: Application to a Parameter Identification Problem in Pharmacokinetics , 2014, SIAM J. Sci. Comput..

[2]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[3]  B. Strom,et al.  Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women , 2013, Breast Cancer Research.

[4]  F. Akiyama,et al.  Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. , 2014, Breast.

[5]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[7]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yusuke Nakamura,et al.  Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients , 2011, Breast Cancer Research and Treatment.

[9]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[10]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Brauch,et al.  Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.

[12]  T. Eissing,et al.  Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling , 2014, SpringerPlus.

[13]  Y. Yap,et al.  Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. , 2011, British journal of clinical pharmacology.

[14]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[15]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[16]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[17]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  Kyle T. Matschke,et al.  Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. , 2014, International journal of clinical pharmacology and therapeutics.

[19]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British Journal of Clinical Pharmacology.

[20]  T. Skaar,et al.  Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen , 2005, Cancer Chemotherapy and Pharmacology.

[21]  T. Eissing,et al.  Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance , 2012, Front. Pharmacol..

[22]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[23]  K. Maeda,et al.  Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method , 2016, Clinical pharmacology and therapeutics.

[24]  Y. Sugiyama,et al.  Inter-individual variability of in vivo CYP2D6 activity in different genotypes. , 2012, Drug metabolism and pharmacokinetics.

[25]  M. Beckmann,et al.  CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations , 2013, Clinical pharmacology and therapeutics.

[26]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[27]  Yuichi Sugiyama,et al.  Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects , 2017, Pharmaceutical Research.

[28]  T. Mushiroda,et al.  Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity , 2014, CPT: pharmacometrics & systems pharmacology.

[29]  Hyeong-Seok Lim,et al.  Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Whirl‐Carrillo,et al.  Prediction of CYP2D6 phenotype from genotype across world populations , 2016, Genetics in Medicine.

[31]  Akihiko Konagaya,et al.  Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models , 2013, BMC Systems Biology.